Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-07-02
2011-10-04
Kosar, Andrew D (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S250000
Reexamination Certificate
active
08030321
ABSTRACT:
Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H4receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
REFERENCES:
patent: 3706747 (1972-12-01), De Angelis et al.
patent: 3755583 (1973-08-01), De Angelis et al.
patent: 4703053 (1987-10-01), Connor et al.
patent: 6080745 (2000-06-01), Davey et al.
patent: 6482948 (2002-11-01), Yamada et al.
patent: 6875781 (2005-04-01), Hong et al.
patent: 7253200 (2007-08-01), Buzard et al.
patent: 7291733 (2007-11-01), Cywin et al.
patent: 2004/0058940 (2004-03-01), Eggenweiler et al.
patent: 2005/0153989 (2005-07-01), Grotzfeld et al.
patent: 2005/0197354 (2005-09-01), Andries et al.
patent: 2006/0111416 (2006-05-01), Lane et al.
patent: 1767537 (2007-03-01), None
patent: 06220059 (1994-08-01), None
patent: 06220059 (1994-08-01), None
patent: WO 2005/042500 (2005-05-01), None
patent: WO 2005/069865 (2005-08-01), None
patent: WO 2006/050965 (2006-05-01), None
patent: WO 2007/090852 (2007-08-01), None
patent: WO 2007/090853 (2007-08-01), None
patent: WO 2007/090854 (2007-08-01), None
patent: WO 2008/074445 (2008-06-01), None
patent: WO 2009/068512 (2009-06-01), None
Amin, K. et al. Inflammation and Structural Changes in the Airways of Patients with Atopic and Nonatopic Asthma. Am. J. Resp. Crit. Care Med. 2000, 162(6), 2295-2301.
Banker, G.S. et al. Modern Pharmaceutics, Marcel Dekker: New York, 1996, pp. 451, 596.
Chen et al. Synthesis of Benxo[b]furans via Cul-Catalyzed Ring Closure. Jour. Organic Chemistry, 2005, vol. 70, No. 17, pp. 6964-6967.
Bell, J.K. et al. Involvement of histamine H4and H1receptors in scratching induced by histamine receptor agonists in BalbC mice. Br. J. Pharmacol. 2004, 142(2), 374-380.
Benoist, C. et al. Mast cells in autoimmune disease. Nature 2002, 420(6917), 875-878.
Buckland, K.F. et al. Histamine induces cytoskeletal changes in human eosinophils via the H4receptor. Br. J. Pharmacol. 2003, 140(6), 1117-1127.
Coge, F. et al. Structure and Expression of the Human Histamine H4-Receptor Gene. Biochem. Biophys. Res. Commun. 2001, 284(2), 301-309.
Cohen, J. The immunopathogenesis of sepsis. Nature 2002, 420(6917), 885-891.
Coussens, L.M. et al. Inflammation and cancer. Nature 2002, 420(6917), 860-867.
Crimi, E. et al. Increased numbers of mast cells in bronchial mucosa after the late-phase asthmatic response to allergen. Am. Rev. Respir. Dis. 1991, 144(6), 1282-1286.
de Esch, I.J.P. et al. The histamine H4receptor as a new therapeutic target for inflammation. Trends Pharmacol. Sci. 2005, 26(9), 462-469.
Fokkens, W.J. et al. Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non-allergic controls: a biopsy study. Clin. Exp. Allergy 1992, 22(7), 701-710.
Fung-Leung, W.-P. et al. Histamine H4 receptor antagonists: The new antihistamines? Curr. Opin. Invest. Drugs 2004, 5(11), 1174-1183.
Gantner, F. et al. Histamine H4and H2Receptors Control Histamine-Induced Interleukin-16 Release from Human CD8+T Cells. J. Pharmacol. Exp. Ther. 2002, 303(1), 300-307.
Gauvreau, G.M. et al. Increased Numbers of Both Airway Basophils and Mast Cells in Sputum after Allergen Inhalation Challenge of Atopic Asthmatics. Am. J. Resp. Crit. Care Med. 2000, 161(5), 1473-1478.
Gutzmer, R. et al. Histamine H4Receptor Stimulation Suppresses IL-12p70 Production and Mediates Chemotaxis in Human Monocyte-Derived Dendritic Cells. J. Immunol. 2005, 174(9), 5224-5232.
Hofstra, C.L. et al. Histamine H4Receptor Mediates Chemotaxis and Calcium Mobilization of Mast Cells. J. Pharmacol. Exp. Ther. 2003, 305(3), 1212-1221.
Ikawa, Y. et al. Histamine H4Receptor Expression in Human Synovial Cells Obtained from Patients Suffering from Rheumatoid Arthritis. Biol. Pharm. Bull. 2005, 28(10), 2016-2018.
Kassel, O. et al. Local increase in the number of mast cells and expression of nerve growth factor in the bronchus of asthmatic patients after repeated inhalation of allergen at low-dose. Clin. Exp. Allergy 2001, 31(9), 1432-1440.
Kirby, J.G. et al. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am. Rev. Respir. Dis. 1987, 136(2), 379-383.
Krug, N. et al. Interleukin 16 and T-cell Chemoattractant Activity in Bronchoalveolar Lavage 24 Hours after Allergen Challenge in Asthma. Am. J. Resp. Crit. Care Med. 2000, 162(1), 105-111.
Libby, P. Inflammation in atherosclerosis. Nature 2002, 420, 868-874.
Lim et al. The Emerging Role of the Histamine H4 Receptor in Anti-Inflammatory Therapy. Curr. Topics Med. Chem. 2006, 6, 1365-1373.
Ling, P. et al. Histamine H4receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br. J. Pharmacol. 2004, 142(1), 161-171.
Lippert, U. et al. Human Skin Mast Cells Express H2 and H4, but not H3 Receptors. J. Invest. Dermatol. 2004, 123(1), 116-123.
Liu, C. et al. Cloning and Pharmacological Characterization of a Fourth Histamine Receptor (H4) Expresses in Bone Marrow. Mol. Pharmacol. 2001, 59(3), 420-426.
Mashikian, V.M. et al. Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. J. Allergy Clin. Immunol. 1998, 101 (6, Part 1), 786-792.
Morse, K.L. et al. Cloning and Characterization of a Novel Human Histamine Receptor. J. Pharmacol. Exp. Ther. 2001, 296(3), 1058-1066.
Nathan, C. Points of control in inflammation. Nature 2002, 420(6917), 846-852.
O'Reilly, M. et al. Identification of a H4Receptor on Human Eosinophils—Role in Eosinophil Chemotaxis. J. Recept. Signal Transduction 2002, 22(1-4), 431-448.
Slater, A. et al. Increase in epithelial mast cell numbers in the nasal mucosa of patients with perennial allergic rhinitis. J. Laryngol. Otol. 1996, 110, 929-933.
Steinberg, D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nature Med. 2002, 8(11), 1211-1217.
Takeshita, K. et al. Critical Role of Histamine H4Receptor in Leukotriene B4Production and Mast Cell-Dependent Neutrophil Recruitment Induced by Zymosan in Vivo. J. Pharmacol. Exp. Ther. 2003, 307(3), 1072-1078.
Thurmond, R.L. et al. A Potent and Selective Histamine H4 Receptor Antagonist with Anti-Inflammatory Properties. J. Pharmacol. Exp. Ther. 2004, 309(1), 404-413.
Tracey, K.J. The inflammatory reflex. Nature 2002, 420(6917), 853-859.
Varga, C. et al. Inhibitory effects of histamine H4receptor antagonists on experimental colitis in the rat. Eur. J. Pharmacol. 2005, 522(1-3), 130-138.
Voehringer, D. et al. Type 2 Immunity Reflects Orchestrated Recruitment of Cells Committed to IL-4 Production. Immunity 2004, 20(3), 267-277.
Weiner, H.L. et al. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002, 420(6917), 879-884.
Wolff, M.E. Burger's Medicinal Chemistry and Drug Discovery, 5thEd., vol. 1: Principles and Practice, John Wily & Sons, 1995, p. 975.
Altenbach, Robert et al., Structure-Activity Studies on a Series of a 2-Aminopyrimidine-Containing Histamine H4 Receptor Ligands, Jour. Med. Chem. (2008), 51(20), pp. 6571-6580.
Dunford, P.J. et al. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. Journal of Immunology, 2006. vol. 176(11) , 7062-7070.
Dunford, P.J. et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J. Allergy Clin. Immunol. 2007, vol. 119(1), 176-183.
Horr et al. STAT1 phosphorylation and cleavage is regulated by the histamine (H4) receptor in human atopic and non-atopic lymphocytes. International Immunopharmacology 2006, vol. 6 (10), 1577-1585.
Jablonowski, J. et al., The first potent and selective non-imidazole human histamine H4 receptor antagonists. Journal of Medicinal Chemistry, 2003. vol. 46(19), 3957-3960.
Jiang et al. Cloning and pharmacological characterization of the dog histamine H-4 receptor. European Journal of Pharmacology, 2008. vol. 592(1-3), 26-32.
Chavez Frank
Curtis Michael P.
Edwards James P.
Gomez Laurent
Grice Cheryl A.
Janssen Pharmaceutica NV
Kosar Andrew D
Leeser Erich A
LandOfFree
Benzofuro- and benzothienopyrimidine modulators of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzofuro- and benzothienopyrimidine modulators of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzofuro- and benzothienopyrimidine modulators of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4274033